ABIVAX Société Anonyme (NASDAQ:ABVX) Research Coverage Started at Piper Sandler

Stock analysts at Piper Sandler started coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a report released on Monday, Marketbeat reports. The brokerage set an “overweight” rating and a $42.00 price target on the stock. Piper Sandler’s price objective suggests a potential upside of 180.00% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Guggenheim started coverage on ABIVAX Société Anonyme in a report on Monday. They issued a “buy” rating and a $50.00 price target on the stock. Morgan Stanley raised their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an “equal weight” rating in a research report on Thursday, April 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

ABIVAX Société Anonyme Stock Down 3.4 %

Shares of NASDAQ ABVX opened at $15.00 on Monday. ABIVAX Société Anonyme has a 52 week low of $7.99 and a 52 week high of $17.02. The company has a 50-day moving average of $14.57.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Capstone Investment Advisors LLC acquired a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth $618,000. Ghisallo Capital Management LLC acquired a new stake in shares of ABIVAX Société Anonyme during the fourth quarter valued at $642,000. Rosalind Advisors Inc. purchased a new stake in ABIVAX Société Anonyme during the 1st quarter worth about $5,411,000. Franklin Resources Inc. acquired a new position in ABIVAX Société Anonyme in the 4th quarter valued at about $13,630,000. Finally, Great Point Partners LLC purchased a new position in ABIVAX Société Anonyme in the 4th quarter valued at about $16,585,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.